{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-134970","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.883008+00:00","generated_at":"2026-05-29T05:02:59.939183+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh","bullets":["Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.","Net proceeds to fund onvansertib clinical costs for RAS-mutated metastatic colorectal cancer (mCRC).","New mutual fund and healthcare dedicated investors participated; existing investors also supported.","Expected close Dec 11, 2024; 90-day lock-up for directors and officers on share sales.","TD Cowen lead bookrunner; William Blair, H.C. Wainwright, Craig-Hallum also underwriters."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-134970","json":"https://secwatch.observer/filing/0000950170-24-134970.json","markdown":"https://secwatch.observer/filing/0000950170-24-134970.md","text":"https://secwatch.observer/filing/0000950170-24-134970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/0000950170-24-134970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/crdf-20241210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:02:59.939183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}